Skip to main content

Table 3 Markers of angiogenesis

From: Gene expression in tumor cells and stroma in dsRed 4T1 tumors in eGFP-expressing mice with and without enhanced oxygenation

   Intermittent HBO Daily HBO
   Tumor Stroma Tumor Stroma
Genes Gene name Fold
change
Fold
change
Fold
change
Fold change
Anti-Angiogenic     
Serpinb5 Serine (or cysteine) peptidase inhibitor, clade B, member 5 3.4 1.6 5.0 NS
Csta Cystatin A 0.1 NS NS NS
Thbs1 Thrombospondin1 0.5 0.5 NS NS
Thbs2 Thrombospondin2 NS 2.7 NS 2.5
Thbs3 Thrombospondin3 NS NS 0.7 NS
Thbs4 Thrombospondin4 0.8 NS NS NS
Pro-angiogenic     
HIF1a Hypoxia-inducible factor 1, alpha NS NS 0.7 NS
Pecam1 Platlet/endothelial cell adhesion molecule 1 0.9 0.5 0.6 NS
Vwf Von Willebrand factor homolog 0.7 0.3 NS 0.6
Vegfa Vascular endothelial growth factor A 0.5 0.5 NS 1.4
Vegfb Vascular endothelial growth factor B NS NS 0.7 NS
Vegfc Vascular endothelial growth factor C 0.6 NS 0.5 NS
Pdgfa Platelet derived growth factor, alpha 0.8 0.7 NS NS
Pdgfb Platelet derived growth factor, b 1.2 0.7 NS NS
Pdgfra Platelet derived growth factor receptor, alpha 0.7 2.3 0.5 2.1
Tgfb1 Transforming growth factor, beta 1 NS 0.8 0.8 NS
Il6 Interleukin 6 0.5 NS NS 0.3
Fgfr1 Fibroblast growth factor receptor 1 0.9 NS NS NS
Fgfr3 Fibroblast growth factor receptor 3 0.7 NS 0.7 NS
Egfr Epidermal growth factor receptor 0.5 NS 0.5 2.7
Serpinb2 Serine (or cysteine) peptidase inhibitor, clade B, member 2 0.6 NS NS 0.5
  1. Displayed results are fold change of gene expression in intermittent and daily hyperbaric oxygen (HBO) treated tumors cells compared to untreated control tumor cells, and intermittent and daily HBO treated stromal cells compared to untreated stromal cells. A positive fold change indicates increased expression after treatment. FDR < 0.05%, NS = not significant